Teplizumab Dosing to Preserve Beta Cell Function in Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 1 diabetes (T1D) fail to consistently achieve desired glycemic targets, leading to increased morbidity and mortality, particularly in children and adolescents, due to the autoimmune destruction of insulin-producing beta cells.
Innovation Solution
Administer a 12-day course of teplizumab at a total dose of more than about 9000 μg/m², followed by additional courses as needed, to preserve beta cell function and improve clinical management of T1D, with monitoring of TIGIT+KLRG1+CD8+CD3+ T-cells to adjust treatment intervals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional insulin therapy is used for type 1 diabetes treatment, then glycemic control is maintained, but morbidity and mortality remain increased due to inability to consistently achieve desired glycemic targets
Solution Approach 1:
The patent applies preliminary action by administering teplizumab before complete beta cell destruction occurs. The treatment targets early stage type 1 diabetes (within 6 weeks of diagnosis) to preserve remaining beta cell function before the autoimmune destruction becomes irreversible. This preventive approach aims to maintain endogenous insulin production and avoid the need for immediate insulin dependency.
Solution Approach 2:
The patent uses teplizumab as an intermediary agent that modulates the autoimmune response. Teplizumab acts as a mediator between the immune system and beta cells, selectively targeting and depleting pathogenic CD8+ T cells while preserving regulatory T cells and beta cell function. This intermediary approach allows the body's own immune system to be redirected away from attacking beta cells.
2Reliability
If high dose teplizumab (more than 9000 μg/m²) is administered over 12 days, then beta cell function is preserved and glycemic control improves, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent implements feedback mechanisms by monitoring TIGIT+KLRG1+CD8+ T cell levels to guide treatment decisions. Baseline measurements are taken before treatment, and follow-up measurements at 1-6 months determine whether additional treatment courses are needed. This feedback loop allows dynamic adjustment of the treatment protocol based on individual patient response and immune cell population changes.
Solution Approach 2:
The patent segments the treatment into discrete 12-day courses rather than continuous therapy. Each course consists of specific dosing schedules (e.g., 106 μg/m² on day 1, 425 μg/m² on day 2, 850 μg/m² on days 3-12). Multiple courses can be administered at intervals (1-6 months apart) based on patient response, making the complex treatment protocol more manageable and adaptable.
3Productivity
If teplizumab treatment is administered to preserve beta cell function, then insulin use and HbA1c levels improve, but requires intensive monitoring of TIGIT+KLRG1+CD8+ T-cells and multiple treatment courses
Solution Approach 1:
The patent applies partial action by administering teplizumab in targeted 12-day courses rather than continuous long-term therapy. The treatment focuses on specific time windows (within 6 weeks of diagnosis, or at 1-6 month intervals based on T cell monitoring) when beta cell preservation is most critical. This approach concentrates therapeutic effect during key periods rather than requiring constant treatment.
Data Source
AI summary
Provided herein are a method of treating type 1 diabetes (T1D). In some embodiments, such method can include administering to a subject in need thereof a 12-day course of teplizumab at a total dose of more than about 9000 μg/m2.